Yarrow Bioscience, Inc.
VYNE is a clinical-stage biopharmaceutical company developing therapies for inflammatory and immune-mediated conditions. It has exclusive worldwide rights to research, develop and commercialize products containing certain BET inhibitor compounds, licensed from Tay Therapeutics. Its programs include VYN202, an oral, small-molecule BD2-selective BET inhibitor, and repibresib gel, a topical pan-BD BET inhibitor. VYNE terminated a Phase 2b trial of repibresib in nonsegmental vitiligo and a Phase 1b trial of VYN202 in psoriasis. It has relied on third-party manufacturers for product candidates used in preclinical studies and clinical trials. Following a merger with Yarrow Bioscience, the combined company plans to focus on YB-101, also known as GS-098, a clinical-stage TSHR antibody for Graves Disease, and explore a clinical development plan for Thyroid Eye Disease. VYNE is based in New Haven, Connecticut.
No SEC Form 4 filings for $YARW in the last 30 days.
See all $YARW insider activity →Guggenheim initiated coverage of Yarrow Bioscience (NASDAQ:YARW) with a Buy rating and $60 price target, citing potential in Graves' disease treatment. The firm estimates a $15B-$20B market, with Yarrow's lead asset, YB-101, showing promise in early trials. Guggenheim projects peak sales of $2.5B for YB-101, driving the price target.
Analysts made several rating changes: Seaport upgraded SiTime (SITM) to Buy with a $425 target, citing AI cycle potential. Wells Fargo upgraded Becton Dickinson (BDX) to Overweight with a $242 target, expecting improved growth. Roth upgraded Centrus Energy (LEU) to Buy with a $115 target, noting acquisition benefits. JPMorgan upgraded SQM (SQM) to Overweight with a $71 target, seeing valuation support.
Analysts upgraded Becton Dickinson (NYSE: BDX) to Overweight with a $242 target, JinkoSolar (NYSE: JKS) to Buy with a $17 target, SiTime (NASDAQ: SITM) to Buy with a $425 target, and Steven Madden (NASDAQ: SHOO) to Hold. Downgrades include BJ’s Wholesale Club (NYSE: BJ) to Neutral, Cogent Communications (NASDAQ: CCOI) to Sector Weight, Molson Coors (NYSE: TAP) to Underweight, and Pfizer (NYSE: PFE) to Hold. Initiations include Fervo Energy (NASDAQ: FRVO) with a Buy rating and $17 target.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning YARW (Yarrow Bioscience, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent YARW coverage spans financial news, corporate actions and market movers.
The upgrade and price target are likely to drive further buying pressure as investors price in the upside potential of YB-101.
Positive outlook from large market opportunity.
Buy initiation could drive gains.
The capital raise provides significant cash for R&D and may dilute existing shareholders, likely supporting short‑term price volatility.
The pricing dilutes existing shareholders and triggers a near-term price decline.
AlphAI scores every news story that mentions YARW with an AI model for sentiment and relevance, and aggregates insider trades from Yarrow Bioscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim initiated coverage of Yarrow Bioscience (NASDAQ:YARW) with a Buy rating and $60 price target, citing potential in Graves' disease treatment. The firm estimates a $15B-$20B market, with Yarrow's lead asset, YB-101, showing promise in early trials. Guggenheim projects peak sales of $2.5B for YB-101, driving the price target.
Analysts made several rating changes: Seaport upgraded SiTime (SITM) to Buy with a $425 target, citing AI cycle potential. Wells Fargo upgraded Becton Dickinson (BDX) to Overweight with a $242 target, expecting improved growth. Roth upgraded Centrus Energy (LEU) to Buy with a $115 target, noting acquisition benefits. JPMorgan upgraded SQM (SQM) to Overweight with a $71 target, seeing valuation support.
Analysts upgraded Becton Dickinson (NYSE: BDX) to Overweight with a $242 target, JinkoSolar (NYSE: JKS) to Buy with a $17 target, SiTime (NASDAQ: SITM) to Buy with a $425 target, and Steven Madden (NASDAQ: SHOO) to Hold. Downgrades include BJ’s Wholesale Club (NYSE: BJ) to Neutral, Cogent Communications (NASDAQ: CCOI) to Sector Weight, Molson Coors (NYSE: TAP) to Underweight, and Pfizer (NYSE: PFE) to Hold. Initiations include Fervo Energy (NASDAQ: FRVO) with a Buy rating and $17 target.
Yarrow Bioscience, Inc. (YARW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Yarrow Bioscience, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as the representative
Yarrow Bioscience Inc (YARW) shares fell 7% after pricing a $150 million public offering of 5.8 million shares at $26 each. The stock is currently trading at $26.55, down 6.65% from the previous close of $28.44 on the Nasdaq.
Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.
Yarrow Bioscience, Inc. disclosed in a Schedule 13G/A that Logos Global Management LP and related funds report beneficial ownership of 286,308 shares, or 10.7% of the common stock class, based on 2,669,788 shares outstanding as of July 29, 2026. The group also cites prefunded warrants for 2,201,030 shares excluded under a 9.99% limit.
Biotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.
Yarrow Bioscience (VYNE) holder swaps 133K shares for warrants Rhea-AI Filing Summary Yarrow Bioscience, Inc. reports that an affiliated RTW Entity managed by RTW Fund Group GP, LLC exchanged 133,290 shares of common stock for pre-funded warrants to purchase the same number of shares on July 29, 2026.
Yarrow Bioscience, Inc. (VYNE) holders report 8,816,429 pre-funded warrants Rhea-AI Filing Summary RTW Fund Group GP, LLC and Roderick Wong, M.D., reported as ten percent owners of Yarrow Bioscience, Inc., disclose indirect holdings received in a July 27, 2026 merger: 399,597 shares of common stock and pre-funded warrants exercisable at $0.0001 for 8,816,429 shares, subject to a 9.99% beneficial ownership cap.
